Amgen — May 1, 2025 release
Fiscal 2025 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000318154-25-000018
Showing in the filing
GAAP tax rate
“11.0 % — 12.5 %”
Period
FY2025
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 8
Dividend for Q1 FY2025
“$2.38”
Total revenues for FY2025
“$34.3 billion to $35.7 billion”
Capital expenditures for FY2025
“approximately $2.3 billion”
Share repurchases for FY2025
“not to exceed $500 million”
GAAP diluted EPS for FY2025
“$ 12.21 — $ 13.46”
Non-GAAP diluted EPS for FY2025
“$ 20.00 — $ 21.20”
GAAP tax rate for FY2025
“11.0 % — 12.5 %”
Non-GAAP tax rate for FY2025
“14.5 % — 16.0 %”
Exhibit 99.1 · the passage around this item
… earlier in the release
The stated guidance also includes the estimated impact of implemented tariffs, but does not account for any tariffs that could be implemented in the future, including potential sector-specific tariffs. Reconciliation of GAAP Tax Rate Guidance to Non-GAAP Tax Rate Guidance for the Year Ending December 31, 2025 (Unaudited) GAAP tax rate guidance 11.0 % — 12.5 % Tax rate of known adjustments discussed above 3.5 % Non-GAAP tax rate guidance 14.5 % — 16.0 %
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.